TSHA - Taysha Gene Therapies, Inc.
IEX Last Trade
1.75
0 0%
Share volume: 32,969
Last Updated: Fri 27 Dec 2024 08:30:09 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.75
0.00
0.00%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-08 | 2023-03-28 | 2023-05-11 | 2023-08-14 | 2023-11-14 | 2024-03-19 | 2024-05-14 | |
| Total revenue | 0.000 | 0.000 | 2.502 M | 4.706 M | 2.395 M | 4.746 M | 3.604 M | 3.411 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 2.502 M | 4.706 M | 2.395 M | 4.746 M | 3.604 M | 3.411 M | |
| nan% | inf% | 88.09% | -49.11% | 98.16% | -24.06% | -5.36% | |||
| Operating expenses | 32.985 M | 25.074 M | 21.202 M | 21.265 M | 25.779 M | 20.380 M | 19.401 M | 27.741 M | |
| Selling general and admin | 9.867 M | 8.683 M | 7.341 M | 8.751 M | 5.988 M | 8.589 M | 6.719 M | 7.084 M | |
| Research and development | 23.118 M | 16.391 M | 13.861 M | 12.514 M | 19.791 M | 11.791 M | 12.682 M | 20.657 M | |
| Total expenses | 32.985 M | 25.074 M | 21.202 M | 21.265 M | 25.779 M | 20.380 M | 19.401 M | 27.741 M | |
| -23.98% | -15.44% | 0.30% | 21.23% | -20.94% | -4.80% | 42.99% | |||
| Operating income | -32.985 M | -25.074 M | -18.700 M | -16.559 M | -23.384 M | -15.634 M | -15.797 M | -24.330 M | |
| Ebit | -32.985 M | -25.074 M | -18.700 M | -16.559 M | -23.384 M | -15.634 M | -15.797 M | -24.330 M | |
| Pretax income | -33.873 M | -26.307 M | -55.723 M | -17.622 M | -24.598 M | -117.087 M | 47.741 M | -24.061 M | |
| -22.34% | 111.82% | -68.38% | 39.59% | 376.00% | -140.77% | -150.40% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -33.873 M | -26.307 M | -55.723 M | -17.622 M | -24.598 M | -117.087 M | 47.741 M | -24.061 M | |
| 22.34% | -111.82% | 68.38% | -39.59% | -376.00% | 140.77% | -150.40% | |||
| Net income | -33.873 M | -26.307 M | -55.723 M | -17.622 M | -24.598 M | -117.087 M | 47.741 M | -24.061 M | |
| 22.34% | -111.82% | 68.38% | -39.59% | -376.00% | 140.77% | -150.40% |